Crossmark

Retrospective chart review and clinical experience of using fully ablative carbon dioxide laser assisted photodynamic therapy to treat basal cell carcinoma with 2 year outcomes

Crossref DOI link: https://doi.org/10.1007/s10103-026-04823-6

Published Online: 2026-02-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Godinho Ramos, Sophie

Nevitte, Louise

Hitchens, Emma

Stevenson, Polly

Vilenchik, Victoria

Singh Thandi, Charankumal

Keith, Daniel
License Information

Text and Data Mining valid from 2026-02-04

Version of Record valid from 2026-02-04
More Information

Article History

Received: 12 May 2025

Accepted: 28 January 2026

First Online: 4 February 2026

Declarations

:

: Not applicable.

: As an audit of an established clinical service, national research ethics approval was not required. The service was approved as a treatment for basal cell carcinoma by the North Bristol NHS Trust Clinical Ethics and Audit Committee for New Clinical Interventions and from the Bristol North Somerset South Gloucestershire (BNSSG) Joint Formulary Group. The audit was requested and approved by the former as part of clinical governance and for the North Bristol NHS Trust Division of Cancer Services. All patients received standard care as per that policy. All patient participants were informed about the nature and scope of the audit, and written informed consent was obtained from all patients for use of photographs in open publication including online use.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below